The aim of the present study is to explore BIM polymorphism and BIM expression status in EGFR-positive NSCLC patient to be used as the prognostic marker for the treatment outcome of EGFR-TKI therapy and to identified patients who will most benefit from EGFR-TKI treatment and may thus be eligible for the reimbursement of treatment costs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.